X4 Pharmaceuticals Reports Q2 2026 Results and Advances Mavorixafor Development
BOSTON, August 6, 2026 X4 Pharmaceuticals reported second quarter 2026 financial results while highlighting continued progress in the global...
Phase 3 trial
Advertisement
Astellas Advances Menopause Drug Toward Japan Approval
TOKYO, August 7, 2026 Astellas Pharma announced the submission of a New Drug Application (NDA) to Japan’s Ministry of...
Agenus Advances Phase 3 ROBBIN Trial for MSS Colon Cancer
LEXINGTON, Mass., August 6, 2026 Agenus Inc. reported its second-quarter 2026 financial results while outlining significant progress in advancing...
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine
CAMBRIDGE, Mass., Aug. 5, 2026 Moderna, Inc. has received U.S. Food and Drug Administration (FDA) approval for mFLUSIVA® (mRNA-1010),...
CervoMed Shares Neflamapimod Development Update
BOSTON, August 5, 2026 CervoMed announced that its management team will participate in a fireside chat and investor meetings...
Advertisements
Allergan Aesthetics Secures FDA Review for BOTOX Cosmetic
Irvine, California, August 4, 2026 Allergan Aesthetics, an AbbVie company, has announced that the U.S. Food and Drug Administration...
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide for MASH
GAITHERSBURG, Md., Aug. 3, 2026 Altimmune, Inc. has initiated patient enrollment in the global PERFORMA Phase 3 registrational trial...
Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2026 Opus Genetics, Inc. has completed patient enrollment in its registrational Phase 3...
Novartis’ Pluvicto Wins FDA Approval for Earlier Prostate Cancer Treatment
SILVER SPRING, Md., July 31, 2026 The U.S. Food and Drug Administration (FDA) has approved Novartis’ Pluvicto (lutetium Lu...
Amgen’s Repatha Wins CHMP Support for Broader Heart Protection
THOUSAND OAKS, Calif., July 29, 2026 Amgen has announced that the Committee for Medicinal Products for Human Use (CHMP)...
Advertisement
